## An Autoinflammatory Disease Due to Homozygous Dele

New England Journal of Medicine 360, 2438-2444 DOI: 10.1056/nejmoa0809568

Citation Report

#	Article	IF	CITATIONS
1	Specific increase inÂcaspase-1 activity andÂsecretion ofÂIL-1 family cytokines: aÂputative link between mevalonate kinase deficiency andÂinflammation. European Cytokine Network, 2009, 20, 101-107.	2.0	43
2	Clinical and basic research papers â $\in$ July 2009. IBMS BoneKEy, 2009, 6, 232-237.	0.0	0
3	Prediction of Candidate Primary Immunodeficiency Disease Genes Using a Support Vector Machine Learning Approach. DNA Research, 2009, 16, 345-351.	3.4	26
4	Immune modulation: IL-1, master mediator or initiator of inflammation. Nature Medicine, 2009, 15, 1363-1364.	30.7	72
5	Blocking Interleukinâ $\in$ I in Rheumatic Diseases. Annals of the New York Academy of Sciences, 2009, 1182, 111-123.	3.8	89
6	Interleukin-1β and the Autoinflammatory Diseases. New England Journal of Medicine, 2009, 360, 2467-2470.	27.0	209
7	TIR8/SIGIRR: an IL-1R/TLR family member with regulatory functions in inflammation and T cell polarization. Trends in Immunology, 2009, 30, 439-446.	6.8	128
8	Therapy of autoinflammatory syndromes. Journal of Allergy and Clinical Immunology, 2009, 124, 1129-1138.	2.9	86
9	Autoinflammation: The prominent role of IL-1 in monogenic autoinflammatory diseases and implications for common illnesses. Journal of Allergy and Clinical Immunology, 2009, 124, 1141-1149.	2.9	129
10	An Autoinflammatory Disease with Deficiency of the Interleukin-1–Receptor Antagonist. New England Journal of Medicine, 2009, 360, 2426-2437.	27.0	892
11	Mutations in the IL1RN locus lead to autoinflammation. Nature Reviews Rheumatology, 2009, 5, 480-482.	8.0	10
13	Clinical, Molecular, and Genetic Characteristics of PAPA Syndrome: A Review. Current Genomics, 2010, 11, 519-527.	1.6	163
14	Treatment of autoinflammatory syndromes. Current Opinion in Pediatrics, 2010, 22, 771-778.	2.0	12
16	Role of IL-1Î <sup>2</sup> in type 2 diabetes. Current Opinion in Endocrinology, Diabetes and Obesity, 2010, 17, 314-321.	2.3	284
17	Hypomorphic Rag mutations can cause destructive midline granulomatous disease. Blood, 2010, 116, 1263-1271.	1.4	110
18	Rationale and efficacy of interleukin-1 targeting in Erdheim–Chester disease. Blood, 2010, 116, 4070-4076.	1.4	129
19	IL-1 pathways in inflammation and human diseases. Nature Reviews Rheumatology, 2010, 6, 232-241.	8.0	689
21	Why not treat human cancer with interleukin-1 blockade?. Cancer and Metastasis Reviews, 2010, 29, 317-329.	5.9	255

#	Article	IF	CITATIONS
22	Interleukin-1, inflammasomes and the skin. European Journal of Cell Biology, 2010, 89, 638-644.	3.6	128
23	Monogenic IL-1 mediated autoinflammatory and immunodeficiency syndromes: Finding the right balance in response to danger signals. Clinical Immunology, 2010, 135, 210-222.	3.2	39
24	The NLRP3 inflammasome, a target for therapy in diverse disease states. European Journal of Immunology, 2010, 40, 631-634.	2.9	46
25	The role of inflammasomes in the immunostimulatory effects of particulate vaccine adjuvants. European Journal of Immunology, 2010, 40, 634-638.	2.9	41
26	Understanding the molecular mechanisms of the multifaceted ILâ€10â€mediated antiâ€inflammatory response: Lessons from neutrophils. European Journal of Immunology, 2010, 40, 2360-2368.	2.9	112
27	rhIL-1Ra reduces hepatocellular apoptosis in mice with acetaminophen-induced acute liver failure. Laboratory Investigation, 2010, 90, 1737-1746.	3.7	32
28	The IL-1 family: regulators of immunity. Nature Reviews Immunology, 2010, 10, 89-102.	22.7	1,149
29	Autoinflammatory Disorders. , 2010, , 232-239.		0
30	SÃndromes autoinflamatórias hereditÃįrias na faixa etÃįria pediÃįtrica. Jornal De Pediatria, 2010, 86, 353-366.	2.0	2
31	Direct Inhibition of Human RANK+ Osteoclast Precursors Identifies a Homeostatic Function of IL-1β. Journal of Immunology, 2010, 185, 5926-5934.	0.8	42
32	Canakinumab. MAbs, 2010, 2, 3-13.	5.2	203
33	Distinct Roles of Hepatocyte- and Myeloid Cell-Derived IL-1 Receptor Antagonist during Endotoxemia and Sterile Inflammation in Mice. Journal of Immunology, 2010, 185, 2516-2524.	0.8	21
34	Uncovering an ILâ€10â€dependent NFâ€KB recruitment to the ILâ€1ra promoter that is impaired in STAT3 functionally defective patients. FASEB Journal, 2010, 24, 1365-1375.	0.5	45
35	Interleukin-1 (IL-1) Pathway. Science Signaling, 2010, 3, cm1.	3.6	589
36	Targeting IL-1β in disease; the expanding role of NLRP3 inflammasome. European Journal of Internal Medicine, 2010, 21, 157-163.	2.2	125
37	Anti-inflammatory Agents: Present and Future. Cell, 2010, 140, 935-950.	28.9	826
38	Autoinflammatory Disease Reloaded: A Clinical Perspective. Cell, 2010, 140, 784-790.	28.9	429
39	Alterations in the self-renewal and differentiation ability of bone marrow mesenchymal stem cells in a mouse model of rheumatoid arthritis. Arthritis Research and Therapy, 2010, 12, R149.	3.5	48

#	Article	IF	CITATIONS
40	Genetics of monogenic autoinflammatory diseases: past successes, future challenges. Nature Reviews Rheumatology, 2011, 7, 469-478.	8.0	95
41	Human TLRs and IL-1Rs in Host Defense: Natural Insights from Evolutionary, Epidemiological, and Clinical Genetics. Annual Review of Immunology, 2011, 29, 447-491.	21.8	316
42	Cytosolic DNA Triggers Inflammasome Activation in Keratinocytes in Psoriatic Lesions. Science Translational Medicine, 2011, 3, 82ra38.	12.4	342
43	Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: Rationale and Design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). American Heart Journal, 2011, 162, 597-605.	2.7	728
45	Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood, 2011, 117, 3720-3732.	1.4	1,683
46	PERIODIC FEVER SYNDROMES AND OTHER INHERITED AUTOINFLAMMATORY DISEASES. , 2011, , 642-660.		12
47	Potential Novel Mechanism for Axenfeld-Rieger Syndrome: Deletion of a Distant Region Containing Regulatory Elements of <i>PITX2</i> ., 2011, 52, 1450.		63
48	Clinical care of children with sterile bone inflammation. Current Opinion in Rheumatology, 2011, 23, 424-431.	4.3	47
49	An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. Yearbook of Medicine, 2011, 2011, 28-29.	0.1	0
50	Are There Patients with Inflammatory Disease Who Do Not Respond to Prednisone?. Yearbook of Medicine, 2011, 2011, 29-31.	0.1	0
51	Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature Syndrome: A Case Report. Pediatric Dermatology, 2011, 28, 538-541.	0.9	45
52	Signal integration, crosstalk mechanisms and networks in the function of inflammatory cytokines. Biochimica Et Biophysica Acta - Molecular Cell Research, 2011, 1813, 2165-2175.	4.1	81
53	Mutations in IL36RN/IL1F5 Are Associated with the Severe Episodic Inflammatory Skin Disease Known as Generalized Pustular Psoriasis. American Journal of Human Genetics, 2011, 89, 432-437.	6.2	468
54	Interleukin-36–Receptor Antagonist Deficiency and Generalized Pustular Psoriasis. New England Journal of Medicine, 2011, 365, 620-628.	27.0	836
56	Cryopyrin-Associated Periodic Syndrome: An Update on Diagnosis and Treatment Response. Current Allergy and Asthma Reports, 2011, 11, 12-20.	5.3	106
57	Interferon regulatory factor 3 plays an anti-inflammatory role in microglia by activating the PI3K/Akt pathway. Journal of Neuroinflammation, 2011, 8, 187.	7.2	115
58	A clinical perspective of ILâ€1β as the gatekeeper of inflammation. European Journal of Immunology, 2011, 41, 1203-1217.	2.9	635
59	SH2â€domain mutations in <i>STAT3</i> in hyperâ€lgE syndrome patients result in impairment of ILâ€10 function. European Journal of Immunology, 2011, 41, 3075-3084.	2.9	26

#	Article	IF	CITATIONS
60	Canakinumab for the treatment of adult and pediatric cryopyrinâ€associated periodic syndromes (CAPS). Drug Development Research, 2011, 72, 553-560.	2.9	0
61	The emerging role of interleukinâ€1β in autoinflammatory diseases. Arthritis and Rheumatism, 2011, 63, 314-324.	6.7	82
62	The first reported case of compound heterozygous IL1RN mutations causing deficiency of the interleukin-1 receptor antagonist. Arthritis and Rheumatism, 2011, 63, 4018-4022.	6.7	61
63	A novel mutation of IL1RN in the deficiency of interleukin-1 receptor antagonist syndrome: Description of two unrelated cases from Brazil. Arthritis and Rheumatism, 2011, 63, 4007-4017.	6.7	96
64	A role of IL-1R1 signaling in the differentiation of Th17 cells and the development of autoimmune diseases. Self/nonself, 2011, 2, 35-42.	2.0	40
66	Combination Therapy with Methotrexate and Etanercept for Refractory Chronic Recurrent Multifocal Osteomyelitis: Figure 1 Journal of Rheumatology, 2011, 38, 782-783.	2.0	29
67	Autoinflammation: translating mechanism to therapy. Journal of Leukocyte Biology, 2011, 90, 37-47.	3.3	30
68	AUTOINFLAMMATORY BONE DISORDERS. , 2011, , 661-673.		0
69	Steroids induce a disequilibrium of secreted interleukin-1 receptor antagonist and interleukin-1Â synthesis by human neutrophils. European Respiratory Journal, 2011, 37, 406-415.	6.7	29
70	IL-1 Inhibition in Cryopyrin-Associated Periodic Syndrome and Beyond: A Million Dollar Question about the Injection Schedule of Biotherapies. Dermatology, 2011, 223, 119-121.	2.1	2
71	Hematology and Immunology. , 2012, , 89-95.		0
72	Monogenic causes of inflammatory disease in rheumatology. Current Opinion in Rheumatology, 2012, 24, 506-514.	4.3	4
73	Diffuse and interstitial lung disease and childhood rheumatologic disorders. Current Opinion in Rheumatology, 2012, 24, 530-540.	4.3	16
74	Effect of interleukin 1β inhibition in cardiovascular disease. Current Opinion in Lipidology, 2012, 23, 548-553.	2.7	68
75	Impact of IL-1 signalling on experimental uveitis and arthritis. Annals of the Rheumatic Diseases, 2012, 71, 753-760.	0.9	30
76	Chronic Cutaneous Pustulosis Due to a 175-kb Deletion on Chromosome 2q13. Archives of Dermatology, 2012, 148, 301.	1.4	52
77	Acitretin- and Tumor Necrosis Factor Inhibitor –Resistant Acrodermatitis Continua of Hallopeau Responsive to the Interleukin 1 Receptor Antagonist Anakinra. Archives of Dermatology, 2012, 148, 297.	1.4	39
78	Inflammasomes and viruses: cellular defence versus viral offence. Journal of General Virology, 2012, 93, 2063-2075.	2.9	65

#	Article	IF	CITATIONS
79	TIR8/SIGIRR is an Interleukin-1 Receptor/Toll Like Receptor Family Member with Regulatory Functions in Inflammation and Immunity. Frontiers in Immunology, 2012, 3, 322.	4.8	67
80	DIRA, DITRA, and New Insights Into Pathways of Skin Inflammation. Archives of Dermatology, 2012, 148, 381.	1.4	60
81	Biologic drugs in autoinflammatory syndromes. Autoimmunity Reviews, 2012, 12, 81-86.	5.8	57
82	A novel mutation in the interleukin-1 receptor antagonist associated with intrauterine disease onset. Clinical Immunology, 2012, 145, 77-81.	3.2	54
84	IL-1β mediates chronic intestinal inflammation by promoting the accumulation of IL-17A secreting innate lymphoid cells and CD4+ Th17 cells. Journal of Experimental Medicine, 2012, 209, 1595-1609.	8.5	485
85	Anakinra as an interleukin 1 receptor antagonist, complicated genetics and molecular impacts- from the point of view of mouse genomics. International Immunopharmacology, 2012, 13, 28-36.	3.8	11
86	Transgenic over-expression of interleukin-33 in osteoblasts results in decreased osteoclastogenesis. Biochemical and Biophysical Research Communications, 2012, 417, 217-222.	2.1	44
87	Inflammasomes as molecular mediators of inflammation and cancer: Potential role in melanoma. Cancer Letters, 2012, 314, 24-33.	7.2	103
88	p65-Dependent production of interleukin-1β by osteolytic prostate cancer cells causes an induction of chemokine expression in osteoblasts. Cancer Letters, 2012, 317, 106-113.	7.2	20
89	Identification, cloning and characterisation of interleukin-1F5 (IL-36RN) in the chicken. Developmental and Comparative Immunology, 2012, 38, 136-147.	2.3	10
90	Sequencing and comparative genomic analysis of 1227 Felis catus cDNA sequences enriched for developmental, clinical and nutritional phenotypes. BMC Genomics, 2012, 13, 31.	2.8	9
91	Genetic support for the role of the <scp>NLRP</scp> 3 inflammasome in psoriasis susceptibility. Experimental Dermatology, 2012, 21, 932-937.	2.9	91
92	Interleukin-1, inflammasomes, autoinflammation and the skin. Swiss Medical Weekly, 2012, 142, w13590.	1.6	93
93	Biochemical regulation of the inflammasome. Critical Reviews in Biochemistry and Molecular Biology, 2012, 47, 424-443.	5.2	114
94	Interleukin 1 Receptor Antagonist Deficiency Presenting as Infantile Pustulosis Mimicking Infantile Pustular Psoriasis. Archives of Dermatology, 2012, 148, 747-52.	1.4	60
95	Rare hereditary autoinflammatory disorders: Towards an understanding of critical in vivo inflammatory pathways. Journal of Dermatological Science, 2012, 66, 183-189.	1.9	14
96	Autoinflammatory syndromes and cellular responses to stress: pathophysiology, diagnosis and new treatment perspectives. Best Practice and Research in Clinical Rheumatology, 2012, 26, 505-533.	3.3	52
97	After GWAS: mice to the rescue?. Current Opinion in Immunology, 2012, 24, 564-570.	5.5	27

# 98	ARTICLE Autoinflammatory Syndromes. Pediatric Clinics of North America, 2012, 59, 447-470.	IF 1.8	Citations 33
99	Type I IFN-mediated regulation of IL-1 production in inflammatory disorders. Cellular and Molecular Life Sciences, 2012, 69, 3395-3418.	5.4	32
100	Neonatal Thrombosis. , 0, , 277-285.		0
101	Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nature Reviews Drug Discovery, 2012, 11, 633-652.	46.4	1,479
102	Mice deficient in hepatocyteâ€specific <scp>IL</scp> â€1Ra show delayed resolution of concanavalin <scp>A</scp> â€induced hepatitis. European Journal of Immunology, 2012, 42, 1294-1303.	2.9	16
103	Current Understanding of the Pathogenesis and Management of Chronic Recurrent Multifocal Osteomyelitis. Current Rheumatology Reports, 2012, 14, 130-141.	4.7	164
104	Deficiency of interleukin-1-receptor antagonist syndrome: a rare auto-inflammatory condition that mimics multiple classic radiographic findings. Pediatric Radiology, 2012, 42, 495-498.	2.0	27
105	Immunology in clinic review series; focus on autoinflammatory diseases: update on monogenic autoinflammatory diseases: the role of interleukin (IL)-1 and an emerging role for cytokines beyond IL-1. Clinical and Experimental Immunology, 2012, 167, 391-404.	2.6	123
106	An autoinflammatory neurological disease due to interleukin 6 hypersecretion. Journal of Neuroinflammation, 2013, 10, 29.	7.2	11
107	Update on the Treatment of Juvenile Idiopathic Arthritis. Current Allergy and Asthma Reports, 2013, 13, 337-346.	5.3	33
108	Anti-Viral and Anti-Inflammatory Mechanisms of the Innate Immune Transcription Factor Interferon Regulatory Factor 3: Relevance to Human CNS Diseases. Journal of NeuroImmune Pharmacology, 2013, 8, 132-144.	4.1	34
110	Concepto y clasificación de los sÃndromes autoinflamatorios. Piel, 2013, 28, 146-153.	0.0	2
111	Introduction to Autoinflammatory Syndromes and Diseases. Dermatologic Clinics, 2013, 31, 363-385.	1.7	12
112	Autoinflammatory Pustular Neutrophilic Diseases. Dermatologic Clinics, 2013, 31, 405-425.	1.7	85
113	Monogenic Autoinflammatory Diseases. Rheumatic Disease Clinics of North America, 2013, 39, 701-734.	1.9	38
114	Interleukin-18, more than a Th1 cytokine. Seminars in Immunology, 2013, 25, 439-448.	5.6	236
115	Exome Sequencing Reveals RAG1 Mutations in a Child with Autoimmunity and Sterile Chronic Multifocal Osteomyelitis Evolving into Disseminated Granulomatous Disease. Journal of Clinical Immunology, 2013, 33, 1289-1292.	3.8	39
116	Treating inflammation by blocking interleukin-1 in humans. Seminars in Immunology, 2013, 25, 469-484.	5.6	471

#	Article	IF	CITATIONS
117	The Interleukin-1 Family: Back to the Future. Immunity, 2013, 39, 1003-1018.	14.3	1,560
118	The expanding spectrum of rare monogenic autoinflammatory diseases. Orphanet Journal of Rare Diseases, 2013, 8, 162.	2.7	26
119	Autoinflammatory bone disorders. Clinical Immunology, 2013, 147, 185-196.	3.2	86
120	Antagonists of IL-1R: a patent evaluation (WO2012122985). Expert Opinion on Therapeutic Patents, 2013, 23, 911-914.	5.0	0
121	Activated phenotype of circulating neutrophils in familial Mediterranean fever. Immunobiology, 2013, 218, 892-898.	1.9	22
122	Antiâ€inflammatory cytokines and risk of type 2 diabetes. Diabetes, Obesity and Metabolism, 2013, 15, 39-50.	4.4	137
123	Inflammasome and cytokine blocking strategies in autoinflammatory disorders. Clinical Immunology, 2013, 147, 242-275.	3.2	75
124	Monogenic autoinflammatory diseases: Concept and clinical manifestations. Clinical Immunology, 2013, 147, 155-174.	3.2	174
125	First Clinical Description of an Infant With Interleukin-36-Receptor Antagonist Deficiency Successfully Treated With Anakinra. Pediatrics, 2013, 132, e1043-e1047.	2.1	101
126	Autoinflammatory Bone Diseases. Rheumatic Disease Clinics of North America, 2013, 39, 735-749.	1.9	93
127	Autoinflammatory Disorders, Pain, and Neural Regulation of Inflammation. Dermatologic Clinics, 2013, 31, 461-470.	1.7	6
128	The Central Role of Anti-IL-1 Blockade in the Treatment of Monogenic and Multi-Factorial Autoinflammatory Diseases. Frontiers in Immunology, 2013, 4, 351.	4.8	48
129	Biological Treatments: New Weapons in the Management of Monogenic Autoinflammatory Disorders. Mediators of Inflammation, 2013, 2013, 1-16.	3.0	64
130	Autoinflammatory bone disorders. Current Opinion in Rheumatology, 2013, 25, 658-664.	4.3	51
131	Decoys and Regulatory "Receptors―of the IL-1/Toll-Like Receptor Superfamily. Frontiers in Immunology, 2013, 4, 180.	4.8	53
132	Interleukin-18 and IL-18 Binding Protein. Frontiers in Immunology, 2013, 4, 289.	4.8	714
133	Deficiency of Interleukinâ€1 Receptor Antagonist Responsive to Anakinra. Pediatric Dermatology, 2013, 30, 758-760.	0.9	62
134	Wholeâ€genome copy number variation analysis in anophthalmia and microphthalmia. Clinical Genetics, 2013, 84, 473-481.	2.0	43

#	Article	IF	CITATIONS
135	A Case of Pemphigus Herpetiformis Occurring in a 9‥earâ€Old Boy. Pediatric Dermatology, 2013, 30, 760-762.	0.9	16
136	A clinical and pathomechanistic profile of chronic nonbacterial osteomyelitis/chronic recurrent multifocal osteomyelitis and challenges facing the field. Expert Review of Clinical Immunology, 2013, 9, 845-854.	3.0	49
137	NLRP3 activation induces ASC-dependent programmed necrotic cell death, which leads to neutrophilic inflammation. Cell Death and Disease, 2013, 4, e644-e644.	6.3	63
138	Efficacy of anti-IL-1 treatment in Majeed syndrome. Annals of the Rheumatic Diseases, 2013, 72, 410-413.	0.9	165
139	Chronic Recurrent Multifocal Osteomyelitis and Deficiency of Interleukin-1–receptor Antagonist. Pediatric Infectious Disease Journal, 2013, 32, 94.	2.0	29
140	Delayed Diagnosis of Tuberculous Meningitis due to False-positive Rapid Test for Brucellosis. Pediatric Infectious Disease Journal, 2013, 32, 95.	2.0	1
141	Intracellular Function of Interleukin-1 Receptor Antagonist in Ischemic Cardiomyocytes. PLoS ONE, 2013, 8, e53265.	2.5	16
142	Interleukin-1 Receptor Blockade in Perinatal Brain Injury. Frontiers in Pediatrics, 2014, 2, 108.	1.9	44
143	Interleukin-1 Receptor Antagonist Originating from Bone Marrowderived Cells and Non-bone Marrow-derived Cells Helps to Suppress Arterial Inflammation and Reduce Neointimal Formation after Injury. Journal of Atherosclerosis and Thrombosis, 2014, 21, 1208-1218.	2.0	10
144	An Expanding Role for Interleukin-1 Blockade from Gout to Cancer. Molecular Medicine, 2014, 20, S43-S58.	4.4	87
147	Untangling the Web of Systemic Autoinflammatory Diseases. Mediators of Inflammation, 2014, 2014, 1-15.	3.0	25
148	Autoinflammatory Diseases Predominantly Affecting Bone and Joints. , 2014, , 551-572.		0
149	Autoinflammatory Diseases (AID). Klinische Padiatrie, 2014, 226, 133-142.	0.6	3
150	Genetic Determinants of Circulating Interleukin-1 Receptor Antagonist Levels and Their Association With Glycemic Traits. Diabetes, 2014, 63, 4343-4359.	0.6	40
151	The Inflammasomes in Autoinflammatory Diseases with Skin Involvement. Journal of Investigative Dermatology, 2014, 134, 1805-1810.	0.7	47
152	Impaired cytokine responses in patients with cryopyrin-associated periodic syndrome (CAPS). Clinical and Experimental Immunology, 2014, 177, 720-731.	2.6	19
153	When less is more. Current Opinion in Allergy and Clinical Immunology, 2014, 14, 491-500.	2.3	29
154	Autoinflammatory syndromes for the dermatologist. Clinics in Dermatology, 2014, 32, 488-501.	1.6	25

#	Article	IF	Citations
155	Caspase-1: The inflammasome and beyond. Innate Immunity, 2014, 20, 115-125.	2.4	178
156	Cytokine Frontiers. , 2014, , .		25
157	Autoinflammatory diseases. Immunology Letters, 2014, 161, 226-230.	2.5	24
158	Guidelines for genetic studies in single patients: lessons from primary immunodeficiencies. Journal of Experimental Medicine, 2014, 211, 2137-2149.	8.5	218
159	Rheumatological disorders and fever. Current Medicine Research and Practice, 2014, 4, 177-183.	0.1	0
160	Monogenic autoinflammatory diseases. Rheumatology, 2014, 53, 1927-1939.	1.9	27
161	IL-1 Blockade in Autoinflammatory Syndromes. Annual Review of Medicine, 2014, 65, 223-244.	12.2	273
162	The hereditary autoinflammatory disorders uncovered. Autoimmunity Reviews, 2014, 13, 892-900.	5.8	53
163	New insights into pustular dermatoses in pediatricÂpatients. Journal of the American Academy of Dermatology, 2014, 70, 767-773.	1.2	19
164	A Systematic Review of Systemic Medications for Pustular Psoriasis in Pediatrics. Pediatric Dermatology, 2014, 31, 430-439.	0.9	39
165	Interleukin-1 receptor antagonist deficiency with a novel mutation; late onset and successful treatment with canakinumab: a case report. Journal of Medical Case Reports, 2015, 9, 145.	0.8	35
166	Deficiency of Interleukin-1 Receptor Antagonist (DIRA): Report of the First Indian Patient and a Novel Deletion Affecting IL1RN. Pediatric Rheumatology, 2015, 13, .	2.1	1
167	Primary Chronic Osteomyelitis of the Jaws in Children: An Update on Pathophysiology, Radiological Findings, Treatment Strategies, and Prospective Analysis of Two Cases. Case Reports in Dentistry, 2015, 2015, 1-12.	0.5	19
168	The Role of IL-1 <i>β</i> in the Bone Loss during Rheumatic Diseases. Mediators of Inflammation, 2015, 2015, 1-10.	3.0	146
169	Interleukin-1 Family Cytokines in Liver Diseases. Mediators of Inflammation, 2015, 2015, 1-19.	3.0	44
170	Interleukin-1 as a Common Denominator from Autoinflammatory to Autoimmune Disorders: Premises, Perils, and Perspectives. Mediators of Inflammation, 2015, 2015, 1-21.	3.0	79
171	Adult-onset Still's disease—pathogenesis, clinical manifestations, and new treatment options. Annals of Medicine, 2015, 47, 6-14.	3.8	131
172	Autoimmune Valvular Carditis. Current Allergy and Asthma Reports, 2015, 15, 491.	5.3	13

ARTICLE IF CITATIONS Molecular and functional characterization of an IL-11<sup>2</sup> receptor antagonist in grass carp 173 2.3 27 (Ctenopharyngodon idella). Developmental and Comparative Immunology, 2015, 49, 207-216. Recombinant interleukin-1 receptor antagonist attenuates the severity of chronic pancreatitis 174 4.4 9 induced by TNBS in rats. Biochemical Pharmacology, 2015, 93, 449-460. Molecular Mechanisms in Genetically Defined Autoinflammatory Diseases: Disorders of Amplified 176 21.8 230 Danger Signaling. Annual Review of Immunology, 2015, 33, 823-874. IL-1 Receptor Antagonist Chimeric Protein: Context-Specific and Inflammation-Restricted Activation. Journal of Immunology, 2015, 195, 1705-1712. Treating rheumatological diseases and co-morbidities with interleukin-1 blocking therapies. 179 1.9 91 Rheumatology, 2015, 54, kev269. Interleukin-1 (IL-1) Signaling in Intestinal Stromal Cells Controls KC/CXCL1 Secretion, Which Correlates with Recruitment of IL-22-Secreting Neutrophils at Early Stages of Citrobacter rodentium 2.2 Infection. Infection and Immunity, 2015, 83, 3257-3267. The interleukin (IL)-1 cytokine family – Balance between agonists and antagonists in inflammatory 181 3.2 385 diseases. Cytokine, 2015, 76, 25-37. IL-1 receptor antagonist-deficient mice develop autoimmune arthritis due to intrinsic activation of 12.8 IL-17-producing CČR2+VÎ<sup>3</sup>6+Î<sup>3</sup>δT cells. Nature Communications, 2015, 6, 7464. New discoveries in CRMO: IL-11<sup>2</sup>, the neutrophil, and the microbiome implicated in disease pathogenesis in 183 6.1 40 Pstpip2-deficient mice. Seminars in Immunopathology, 2015, 37, 407-412. Sharpin Controls Osteogenic Differentiation of Mesenchymal Bone Marrow Cells. Journal of 184 0.8 Immunology, 2015, 195, 3675-3684. Practice parameter for the diagnosis and management of primary immunodeficiency. Journal of Allergy 185 2.9 564 and Clinical Immunology, 2015, 136, 1186-1205.e78. The SAPHO syndrome revisited with an emphasis on spinal manifestations. Skeletal Radiology, 2015, 44, 9-24. New players driving inflammation in monogenic autoinflammatory diseases. Nature Reviews 187 8.0 57 Rheumatology, 2015, 11, 11-20. The Interleukin-1 Family., 2016, , 438-446. Regulatory Role of IL-1R8 in Immunity and Disease. Frontiers in Immunology, 2016, 7, 149. 189 73 4.8 Cell death and inflammation: the case for <scp>IL</scp>â€1 family cytokines as the canonical 147 <scp>DAMP</scp>s of the immune system. FEBS Journal, 2016, 283, 2599-2615. Apoptotic Cells Release IL1 Receptor Antagonist in Response to Genotoxic Stress. Cancer Immunology 192 3.4 8 Research, 2016, 4, 294-302. Anti-inflammatory panacea? The expanding therapeutics of interleukin-1 blockade. Current Opinion in 4.3 Rheumatology, 2016, 28, 197-203.

#	Article	IF	Citations
194	Autoinflammatory Disorders in Children. Handbook of Systemic Autoimmune Diseases, 2016, , 267-304.	0.1	0
195	Chronic Recurrent Multifocal Osteomyelitis and Related Disorders. Handbook of Systemic Autoimmune Diseases, 2016, , 315-339.	0.1	1
196	An NLRP3 Mutation Causes Arthropathy and Osteoporosis in Humanized Mice. Cell Reports, 2016, 17, 3077-3088.	6.4	45
197	Autoinflammation and HLA-B27: Beyond Antigen Presentation. Ocular Immunology and Inflammation, 2016, 24, 460-469.	1.8	14
198	Microbiota and caspase-1/caspase-8 regulate IL-1Î <sup>2</sup> -mediated bone disease. Gut Microbes, 2016, 7, 334-341.	9.8	13
199	Chronic Nonbacterial Osteomyelitis: Pathophysiological Concepts and Current Treatment Strategies. Journal of Rheumatology, 2016, 43, 1956-1964.	2.0	84
200	Periodic fevers and autoinflammatory syndromes in childhood. Journal of Paediatrics and Child Health, 2016, 52, 865-871.	0.8	9
201	Genetically defined autoinflammatory diseases. Oral Diseases, 2016, 22, 591-604.	3.0	22
202	The challenge of autoinflammatory syndromes: with an emphasis on hyper-IgD syndrome. Rheumatology, 2016, 55, ii23-ii29.	1.9	12
203	Interleukin-36 potently stimulates human M2 macrophages, Langerhans cells and keratinocytes to produce pro-inflammatory cytokines. Cytokine, 2016, 84, 88-98.	3.2	70
204	Periodic Fever Syndromes and Other Inherited Autoinflammatory Diseases. , 2016, , 609-626.e8.		13
205	Autoinflammatory Bone Disorders. , 2016, , 627-641.e5.		3
206	Recurrent Fevers for the Pediatric Immunologist: It's Not All Immunodeficiency. Current Allergy and Asthma Reports, 2016, 16, 2.	5.3	9
207	Primary immunodeficiency in the neonate: Early diagnosis and management. Seminars in Fetal and Neonatal Medicine, 2016, 21, 35-43.	2.3	21
208	Targeting the inflammasome in rheumatic diseases. Translational Research, 2016, 167, 125-137.	5.0	11
209	Autoinflammatory Disorders. , 2016, , 133-142.e3.		Ο
210	A systematic approach to autoinflammatory syndromes: a spelling booklet for the beginner. Expert Review of Clinical Immunology, 2017, 13, 571-597.	3.0	57
212	Deficiency of Interleukin-1 Receptor Antagonist (DIRA): Report of the First Indian Patient and a Novel Deletion Affecting IL1RN. Journal of Clinical Immunology, 2017, 37, 445-451.	3.8	43

#	Article	IF	CITATIONS
213	Primary Immunodeficiency Diseases. , 2017, , .		22
215	Dermatologic Manifestations of Monogenic Autoinflammatory Diseases. Dermatologic Clinics, 2017, 35, 21-38.	1.7	38
216	Chronic Recurrent Multifocal Osteomyelitis and Related Diseases—Update on Pathogenesis. Current Rheumatology Reports, 2017, 19, 18.	4.7	38
217	Phosphodiesterase 4B negatively regulates endotoxin-activated interleukin-1 receptor antagonist responses in macrophages. Scientific Reports, 2017, 7, 46165.	3.3	12
218	The monogenic autoinflammatory diseases define new pathways in human innate immunity and inflammation. Nature Immunology, 2017, 18, 832-842.	14.5	301
219	Identification of potential biomarkers and therapeutic targets for human IgA nephropathy and hypertensive nephropathy by bioinformatics analysis. Molecular Medicine Reports, 2017, 16, 3087-3094.	2.4	11
220	Enfermedades autoinflamatorias en dermatologÃa pediátrica. Parte 2: sÃndromes histiocÃtico-macrofágicos y sÃndromes vasculopáticos. Actas Dermo-sifiliográficas, 2017, 108, 620-629.	0.4	2
221	Autoinflammatory Diseases in Pediatric Dermatology–Part 2: Histiocytic, Macrophage Activation, and Vasculitis Syndromes. Actas Dermo-sifiliográficas, 2017, 108, 620-629.	0.4	1
222	Chronic Recurrent Multifocal Osteomyelitis (CRMO): Presentation, Pathogenesis, and Treatment. Current Osteoporosis Reports, 2017, 15, 542-554.	3.6	171
224	Whole genome sequencing identifies missense mutation in MTBP in Shar-Pei affected with Autoinflammatory Disease (SPAID). BMC Genomics, 2017, 18, 348.	2.8	9
225	HMGB1, IL-1α, IL-33 and S100 proteins: dual-function alarmins. Cellular and Molecular Immunology, 2017, 14, 43-64.	10.5	333
226	Cytokine signatures in hereditary fever syndromes (HFS). Cytokine and Growth Factor Reviews, 2017, 33, 19-34.	7.2	12
227	When to Suspect Autoinflammatory/Recurrent Fever Syndromes. Pediatric Clinics of North America, 2017, 64, 111-125.	1.8	9
228	6 Quantitative Veräderungen der Zellen des peripheren Blutes. , 2017, , 331-401.		0
229	Potential of IL-1, IL-18 and Inflammasome Inhibition for the Treatment of Inflammatory Skin Diseases. Frontiers in Pharmacology, 2017, 8, 278.	3.5	92
230	Monogenic Autoinflammatory Diseases with Mendelian Inheritance: Genes, Mutations, and Genotype/Phenotype Correlations. Frontiers in Immunology, 2017, 8, 344.	4.8	37
231	Familial Autoinflammatory Syndromes. , 2017, , 1666-1684.e4.		2
232	Pustular psoriasis and related pustular skin diseases. British Journal of Dermatology, 2018, 178, 614-618.	1.5	58

#	ARTICLE TNFAIP3 haploinsufficiency is the cause of autoinflammatory manifestations in a patient with a	IF	CITATIONS
233	deletion of 13Mb on chromosome 6. Clinical Immunology, 2018, 191, 44-51.	3.2	40
234	Chronic recurrent multifocal osteomyelitis in children and adults: current understanding and areas for development. Rheumatology, 2018, 57, 41-48.	1.9	42
235	Are neutrophilic dermatoses autoinflammatory disorders?. British Journal of Dermatology, 2018, 178, 603-613.	1.5	58
236	Geoepidemiology and Immunologic Features of Autoinflammatory Diseases: a Comprehensive Review. Clinical Reviews in Allergy and Immunology, 2018, 54, 454-479.	6.5	27
237	Bone involvement in monogenic autoinflammatory syndromes. Rheumatology, 2018, 57, 606-618.	1.9	15
238	New mosaic tiles in childhood hereditary autoinflammatory disorders. Immunology Letters, 2018, 193, 67-76.	2.5	19
239	Update on the genetics of nonbacterial osteomyelitis in humans. Current Opinion in Rheumatology, 2018, 30, 521-525.	4.3	34
240	Anakinra Therapy for Non-cancer Inflammatory Diseases. Frontiers in Pharmacology, 2018, 9, 1157.	3.5	198
241	Scoping Review on Use of Drugs Targeting Interleukin 1 Pathway in DIRA and DITRA. Dermatology and Therapy, 2018, 8, 539-556.	3.0	23
242	The Role of Interleukin-1 in the Pathogenesis of Cancer and its Potential as a Therapeutic Target in Clinical Practice. Oncology and Therapy, 2018, 6, 109-127.	2.6	81
243	Auto-inflammation and the Skin. , 2018, , 301-318.		0
244	Novel insights into the role of inflammasomes in autoimmune and metabolic rheumatic diseases. Rheumatology International, 2018, 38, 1345-1354.	3.0	18
245	Molecular Basis of Bone Diseases. , 2018, , 627-649.		1
246	Neutrophilic Dermatoses. , 2018, , .		5
247	Decoding inflammation, its causes, genomic responses, and emerging countermeasures. Scandinavian Journal of Immunology, 2019, 90, e12812.	2.7	39
248	Update on the Genetics of Autoinflammatory Disorders. Current Allergy and Asthma Reports, 2019, 19, 41.	5.3	3
249	Dermatologic and Dermatopathologic Features of Monogenic Autoinflammatory Diseases. Frontiers in Immunology, 2019, 10, 2448.	4.8	29
250	Mechanisms of Inflammation in Neutrophil-Mediated Skin Diseases. Frontiers in Immunology, 2019, 10, 1059.	4.8	92

#	Article	IF	CITATIONS
251	Autoinflammatory Disorders: A Review and Update on Pathogenesis and Treatment. American Journal of Clinical Dermatology, 2019, 20, 539-564.	6.7	38
252	Deficiency of the Interleukin-1 Receptor Antagonist (DIRA). , 2019, , 69-83.		0
253	Autoinflammation: Past, Present, and Future. , 2019, , 3-15.		3
254	Classification of Genetically Defined Autoinflammatory Diseases. , 2019, , 167-201.		6
255	Genetic Aspects of Investigating and Understanding Autoinflammation. , 2019, , 19-48.		3
256	Genetic Causes of Inflammatory Bone Disease. , 2019, , 455-470.		0
257	Interleukin (IL)-1 Blocking Compounds and Their Use in Autoinflammatory Diseases. , 2019, , 751-774.		0
258	Functional deficiency in endogenous interleukinâ€1 receptor antagonist in patients with febrile infectionâ€related epilepsy syndrome. Annals of Neurology, 2019, 85, 526-537.	5.3	79
261	Recurrent Fever Syndromes. Rare Rheumatic Diseases, 2019, , 27-58.	0.0	0
262	Inflammasome-Dependent Cytokines at the Crossroads of Health and Autoinflammatory Disease. Cold Spring Harbor Perspectives in Biology, 2019, 11, a028563.	5.5	54
263	Inflammasomes in the pathophysiology of autoinflammatory syndromes. Journal of Leukocyte Biology, 2020, 107, 379-391.	3.3	48
264	Monogenic autoinflammatory disorders: beyond the periodic fever. Internal Medicine Journal, 2020, 50, 151-164.	0.8	6
266	EFLA 945 restricts AIM2 inflammasome activation by preventing DNA entry for psoriasis treatment. Cytokine, 2020, 127, 154951.	3.2	14
267	The role of Interleukin 1 receptor antagonist in mesenchymal stem cellâ€based tissue repair and regeneration. BioFactors, 2020, 46, 263-275.	5.4	65
268	Autoinflammatory Disorders with Perinatal Onset. Clinics in Perinatology, 2020, 47, 41-52.	2.1	0
269	Activation of Toll-Like Receptor 3 Induces Interleukin-1 Receptor Antagonist Expression by Activating the Interferon Regulatory Factor 3. Journal of Innate Immunity, 2020, 12, 304-320.	3.8	16
270	The intrinsic and extrinsic elements regulating inflammation. Life Sciences, 2020, 260, 118258.	4.3	23
271	IL-1 Superfamily Members and Periodontal Diseases. Journal of Dental Research, 2020, 99, 1425-1434.	5.2	44

#	Article	IF	CITATIONS
272	Cutibacterium acnes and autoinflammatory bone disease: Case series of three patients. Clinical Immunology, 2020, 219, 108540.	3.2	0
273	Monogenic autoinflammatory disorders: Conceptual overview, phenotype, and clinical approach. Journal of Allergy and Clinical Immunology, 2020, 146, 925-937.	2.9	89
274	The systemic autoinflammatory disorders for dermatologists. Part 2: disease examples. Clinical and Experimental Dermatology, 2020, 45, 967-973.	1.3	4
276	New variant in the IL1RN-gene (DIRA) associated with late-onset, CRMO-like presentation. Rheumatology, 2020, 59, 3259-3263.	1.9	23
277	The IL1RN Mutation Creating the Most-Upstream Premature Stop Codon Is Hypomorphic Because of a Reinitiation of Translation. Journal of Clinical Immunology, 2020, 40, 643-645.	3.8	1
278	Moving towards personalized treatments of immune-related adverse events. Nature Reviews Clinical Oncology, 2020, 17, 504-515.	27.6	189
279	Homozygous IL1RN Mutation in Siblings with Deficiency of Interleukin-1 Receptor Antagonist (DIRA). Journal of Clinical Immunology, 2020, 40, 637-642.	3.8	9
280	Autoinflammatory diseases affecting bone and joints, and autoinflammatory interferonopathies. , 2020, , 685-720.		1
281	Autoinflammatory diseases predominantly affecting the skin. , 2020, , 737-749.		0
282	Intracellular IL-1 Receptor Antagonist Isoform 1 Released from Keratinocytes upon Cell Death Acts as an Inhibitor for the Alarmin IL-11±. Journal of Immunology, 2020, 204, 967-979.	0.8	8
283	Characterization of a Novel Interleukin-1 Receptor Antagonist from Sheep ( <i>Ovis aries</i> ). Journal of Interferon and Cytokine Research, 2020, 40, 268-278.	1.2	1
284	Lifelong Immune Modulation Versus Hematopoietic Cell Therapy for Inborn Errors of Immunity. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 628-639.	3.8	9
285	Novel Majeed Syndrome–Causing LPIN2 Mutations Link Bone Inflammation to Inflammatory M2 Macrophages and Accelerated Osteoclastogenesis. Arthritis and Rheumatology, 2021, 73, 1021-1032.	5.6	11
286	Colonic mucosal and cytobrush sample cytokine mRNA expression in canine inflammatory bowel disease and their correlation with disease activity, endoscopic and histopathologic score. PLoS ONE, 2021, 16, e0245713.	2.5	3
287	Chronic nonbacterial osteomyelitis (CNO) and chronic recurrent multifocal osteomyelitis (CRMO). Journal of Translational Autoimmunity, 2021, 4, 100095.	4.0	48
288	Autoinflammatory syndromes. JDDG - Journal of the German Society of Dermatology, 2021, 19, 400-426.	0.8	2
289	Majeed Syndrome: A Review of the Clinical, Genetic and Immunologic Features. Biomolecules, 2021, 11, 367.	4.0	19
291	Novel mutation in interleukin 1 receptor antagonist associated with chronic diarrhoea in infancy. Journal of Paediatrics and Child Health, 2022, 58, 186-188.	0.8	3

#	Article	IF	CITATIONS
292	Deficiency of Interleukin-1 Receptor Antagonist: New Genetic Autoinflammatory Disease as a Diagnostic Challenge for Pediatricians. Journal of Pediatric Genetics, 0, , .	0.7	0
293	IL-1 Family Antagonists in Mouse and Human Skin Inflammation. Frontiers in Immunology, 2021, 12, 652846.	4.8	41
294	Genetics of Pediatric Immune-Mediated Diseases and Human Immunity. Annual Review of Immunology, 2021, 39, 227-249.	21.8	9
295	An update on genetic basis of generalized pustular psoriasis (Review). International Journal of Molecular Medicine, 2021, 47, .	4.0	42
296	Monogenic Autoinflammatory Diseases: State of the Art and Future Perspectives. International Journal of Molecular Sciences, 2021, 22, 6360.	4.1	28
297	Chronic Nonbacterial Osteomyelitis in Children. Children, 2021, 8, 551.	1.5	10
298	Human autoinflammatory disease reveals ELF4 as a transcriptional regulator of inflammation. Nature Immunology, 2021, 22, 1118-1126.	14.5	30
299	Generalized Pustular Psoriasis: Divergence of Innate and Adaptive Immunity. International Journal of Molecular Sciences, 2021, 22, 9048.	4.1	22
301	Autoinflammatory Disorders. Rare Diseases of the Immune System, 2021, , 279-313.	0.1	0
302	Autoinflammatory Disorders. , 2017, , 393-435.		1
303	The Interleukin-1 Family. , 2014, , 3-51.		4
304	IL-36: An Epithelial Cytokine Important in Psoriasis. , 2014, , 199-214.		1
305	Hereditary recurrent fevers. , 2011, , 1637-1657.e5.		1
306	Skin Signs of Other Systemic Diseases. , 2011, , 562-579.		2
307	Chronic non-bacterial osteomyelitis and autoinflammatory bone diseases. Clinical Immunology, 2020, 216, 108458.	3.2	15
308	Inhibition of interleukin-6 signaling attenuates aortitis, left ventricular hypertrophy and arthritis in interleukin-1 receptor antagonist deficient mice. Clinical Science, 2020, 134, 2771-2787.	4.3	7
309	Monogenic autoinflammatory diseases: new insights into clinical aspects and pathogenesis. Current Opinion in Rheumatology, 2010, 22, 1.	4.3	55
310	Rilonacept maintains long-term inflammatory remission in patients with deficiency of the IL-1 receptor antagonist. JCI Insight, 2017, 2, .	5.0	35

#	Article	IF	CITATIONS
311	Psoriasiform dermatitis is driven by IL-36–mediated DC-keratinocyte crosstalk. Journal of Clinical Investigation, 2012, 122, 3965-3976.	8.2	352
312	Identification of Potential Small Molecule Allosteric Modulator Sites on IL-1R1 Ectodomain Using Accelerated Conformational Sampling Method. PLoS ONE, 2015, 10, e0118671.	2.5	29
313	Pediatric hereditary autoinflammatory syndromes. Jornal De Pediatria, 2010, 86, 353-366.	2.0	7
314	Pustular Psoriasis: The Dawn of a New Era. Acta Dermato-Venereologica, 2020, 100, 87-93.	1.3	56
315	Spectrum of Genetic Autoinflammatory Diseases Presenting with Cutaneous Symptoms. Acta Dermato-Venereologica, 2020, 100, adv00091-151.	1.3	9
316	Autoinflammatory diseases and the inflammasome: mechanisms of IL-1Î <sup>2</sup> activation leading to neutrophil-rich skin disorders. Inflammation and Regeneration, 2011, 31, 72-80.	3.7	4
317	Periodic fever syndrome and autoinflammatory diseases. F1000 Medicine Reports, 2010, 2, .	2.9	9
318	Genome-wide association studies - A summary for theclinical gastroenterologist. World Journal of Gastroenterology, 2009, 15, 5377.	3.3	14
319	Autoinflammatory syndromes: Fever is not always a sign of infection. Cleveland Clinic Journal of Medicine, 2012, 79, 569-581.	1.3	16
320	The autoinflammatory diseases. Swiss Medical Weekly, 2012, 142, w13602.	1.6	39
321	Molecular biology of autoinflammatory diseases. Inflammation and Regeneration, 2021, 41, 33.	3.7	11
322	Turning on and off the Immunological Switch: Immune Response Polarization and Its Control by IL-10 and STAT3. , 2011, , 27-55.		0
323	Neueste Erkenntnisse und Blick in die Zukunft. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2011, , 1-48.	0.0	0
324	Papulosquamous and Related Disorders. , 2011, , 71-91.		2
326	Coagulation Disorders: Inflammation and Thrombosis. , 2012, , 770-774.		1
327	Kapitel E1 Literaturverzeichnis zu Peter, Pichler, Müller-Ladner (Hrsg.): Klinische Immunologie. , 2012, , e1-e80.		0
328	The Autoinflammatory Diseases. , 2012, , 1701-1711.		0
330	Familial Autoinflammatory Syndromes. , 2013, , 1597-1615.e4.		0

#	Article	IF	CITATIONS
331	Neue Hautkrankheiten. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2013, , 317-328.	0.0	0
332	Comprehensive Review of Rare Hereditary Autoinflammatory Disorders. Journal of Genetic Disorders & Genetic Reports, 2013, 02, .	0.1	1
333	Autoinflammatory Syndromes. , 2015, , 409-414.		0
334	Cytokine neutralizers. , 2015, , 479-484.		1
335	Monogenic autoinflammatory diseases. , 2015, , 1369-1391.		1
336	Autoinflammatory Syndromes: Relevance to Inflammatory Skin Diseases and Personalized Medicine. , 2015, , 101-110.		0
338	Autoinflammatory Diseases. , 2017, , 695-714.		0
339	Deficiency of the IL-1 Receptor Antagonist (DIRA). , 2018, , 1-6.		0
340	Chronic Recurrent Multifocal Osteomyelitis (CRMO). , 2018, , 403-408.		0
341	Development of the doctrine of auto-inflammatory diseases in the XXI century. Nauchno-Prakticheskaya Revmatologiya, 0, 56, 5-18.	1.0	8
342	Rare Monogenic Causes of Periodic Fevers. Rare Diseases of the Immune System, 2020, , 257-272.	0.1	0
343	Systemic Disease and the Skin. , 2022, , 491-601.		0
344	Chronic recurrent multifocal osteomyelitis: diagnosis and treatment. Current Opinion in Pediatrics, 2021, 33, 90-96.	2.0	13
345	Systemic Disease and the Skin. , 2020, , 1-112.		0
346	Precision Medicine in Critical Illness: Sepsis and Acute Respiratory Distress Syndrome. Respiratory Medicine, 2020, , 267-288.	0.1	2
347	Deficiency of the IL-1 Receptor Antagonist (DIRA). , 2020, , 269-274.		0
348	Deficiency of Interleukin 1 Receptor Antagonist (DIRA). , 2020, , 1-4.		0
349	Monogenic Systemic Autoinflammatory Diseases. , 2021, , .		0

#	Article	IF	CITATIONS
350	Multifaceted roles of IL-38 in inflammation and cancer. Cytokine, 2022, 151, 155808.	3.2	12
351	Clinical Decisions in Pediatric Psoriasis. Dermatologic Clinics, 2022, 40, 145-166.	1.7	0
352	What Is IL-1 for? The Functions of Interleukin-1 Across Evolution. Frontiers in Immunology, 2022, 13, 872155.	4.8	20
354	Autoinflammatory disorders. , 2022, , 389-421.		0
355	Inflammasomes and the IL-1 Family in Bone Homeostasis and Disease. Current Osteoporosis Reports, 2022, 20, 170-185.	3.6	9
356	Skin Signs of Other Systemic Diseases. , 2016, , 573-591.e6.		2
357	Papulosquamous and Related Disorders. , 2016, , 73-94.e4.		3
358	IL-1 and autoinflammatory disease: biology, pathogenesis and therapeutic targeting. Nature Reviews Rheumatology, 2022, 18, 448-463.	8.0	47
359	IL-1 family cytokines serve as 'activity recognition receptors' for aberrant protease activity indicative of danger. Cytokine, 2022, 157, 155935.	3.2	10
360	Heterogeneity analysis of astrocytes following spinal cord injury at singleâ€cell resolution. FASEB Journal, 2022, 36, .	0.5	22
362	IL-1 Receptor Antagonist (IL-1Ra) Levels and Management of Metabolic Disorders. Nutrients, 2022, 14, 3422.	4.1	14
363	Therapeutic targeting of inflammasome signaling by blocking interleukin-1. , 2023, , 583-603.		0
364	Dermatologic Manifestations of Noninflammasome-Mediated Autoinflammatory Diseases. JID Innovations, 2023, 3, 100176.	2.4	3
365	The IL-1 Family and Its Role in Atherosclerosis. International Journal of Molecular Sciences, 2023, 24, 17.	4.1	9
366	Autoantibodies neutralizing antiinflammatory mediators in the context of SARS-CoV-2 infection and COVID-19. , 2023, , 351-368.		0
367	Biologics and JAK inhibitors for the treatment of monogenic systemic autoinflammatory diseases in children. Journal of Allergy and Clinical Immunology, 2023, 151, 607-618.	2.9	6
368	Chronic Nonbacterial Osteomyelitis and Inflammatory Bowel Disease: A Literature Review-Based Cohort. Children, 2023, 10, 502.	1.5	1
369	Pediatric autoinflammatory bone disorders—a mini review with special focus on pathogenesis and inborn errors of immunity. Frontiers in Pediatrics, 0, 11,	1.9	1

#	Article	IF	CITATIONS
370	Identification of an IL-1 receptor mutation driving autoinflammation directs IL-1-targeted drug design. Immunity, 2023, 56, 1485-1501.e7.	14.3	9
371	Colchicine-responsive chronic recurrent multifocal osteomyelitis associated with familial Mediterranean fever in the presence of MEFV mutation: A case report. Modern Rheumatology Case Reports, 2023, 8, 195-198.	0.7	0
373	Update on treatment responses and outcome measure development in chronic nonbacterial osteomyelitis. Current Opinion in Rheumatology, 2023, 35, 255-264.	4.3	0
376	How to Build a Fire: The Genetics of Autoinflammatory Diseases. Annual Review of Genetics, 2023, 57, .	7.6	0
377	Pediatric-onset limited ANCA-associated vasculitis arising during pre-existing chronic recurrent multifocal osteomyelitis. Pediatric Rheumatology, 2023, 21, .	2.1	0
378	Accuracy of generative artificial intelligence models in differential diagnoses of familial Mediterranean fever and deficiency of Interleukin-1 receptor antagonist. Journal of Translational Autoimmunity, 2023, 7, 100213.	4.0	3
379	The role of the interleukin-36 axis in generalized pustular psoriasis: a review of the mechanism of action of spesolimab. Frontiers in Immunology, 0, 14, .	4.8	0
380	Case Report: ISG15 deficiency caused by novel variants in two families and effective treatment with Janus kinase inhibition. Frontiers in Immunology, 0, 14, .	4.8	0
381	Analysis of Anakinra Therapy for the Deficiency of Interleukin-1 Receptor Antagonist through Clinical Evidence. Journal of Clinical Medicine, 2024, 13, 1026.	2.4	1
382	Practical Approach to Diagnosis and Management of IL-1-Mediated Autoinflammatory Diseases (CAPS,) Tj ETQq1	$1 \begin{array}{c} 0.7843 \\ 3.1 \end{array}$	14 rgBT /Ove
383	P2RX7 gene variants associate with altered inflammasome assembly and reduced pyroptosis in chronic nonbacterial osteomyelitis (CNO). Journal of Autoimmunity, 2024, 144, 103183.	6.5	0
384	Study on the rationality of small diameter metallic airway stent in treatment of tracheal stenosis in injured rabbits. Journal of Cardiothoracic Surgery, 2024, 19, .	1.1	0
386	Genetic and epigenetic dysregulation of innate immune mechanisms in autoinflammatory diseases. FEBS Journal, 0, , .	4.7	0